1
|
Parker GD, Hanley L, Yu XY. Mass Spectral Imaging to Map Plant-Microbe Interactions. Microorganisms 2023; 11:2045. [PMID: 37630605 PMCID: PMC10459445 DOI: 10.3390/microorganisms11082045] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 07/23/2023] [Accepted: 08/08/2023] [Indexed: 08/27/2023] Open
Abstract
Plant-microbe interactions are of rising interest in plant sustainability, biomass production, plant biology, and systems biology. These interactions have been a challenge to detect until recent advancements in mass spectrometry imaging. Plants and microbes interact in four main regions within the plant, the rhizosphere, endosphere, phyllosphere, and spermosphere. This mini review covers the challenges within investigations of plant and microbe interactions. We highlight the importance of sample preparation and comparisons among time-of-flight secondary ion mass spectroscopy (ToF-SIMS), matrix-assisted laser desorption/ionization (MALDI), laser desorption ionization (LDI/LDPI), and desorption electrospray ionization (DESI) techniques used for the analysis of these interactions. Using mass spectral imaging (MSI) to study plants and microbes offers advantages in understanding microbe and host interactions at the molecular level with single-cell and community communication information. More research utilizing MSI has emerged in the past several years. We first introduce the principles of major MSI techniques that have been employed in the research of microorganisms. An overview of proper sample preparation methods is offered as a prerequisite for successful MSI analysis. Traditionally, dried or cryogenically prepared, frozen samples have been used; however, they do not provide a true representation of the bacterial biofilms compared to living cell analysis and chemical imaging. New developments such as microfluidic devices that can be used under a vacuum are highly desirable for the application of MSI techniques, such as ToF-SIMS, because they have a subcellular spatial resolution to map and image plant and microbe interactions, including the potential to elucidate metabolic pathways and cell-to-cell interactions. Promising results due to recent MSI advancements in the past five years are selected and highlighted. The latest developments utilizing machine learning are captured as an important outlook for maximal output using MSI to study microorganisms.
Collapse
Affiliation(s)
- Gabriel D. Parker
- Department of Chemistry, University of Illinois Chicago, Chicago, IL 60607, USA
| | - Luke Hanley
- Department of Chemistry, University of Illinois Chicago, Chicago, IL 60607, USA
| | - Xiao-Ying Yu
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| |
Collapse
|
2
|
Wittig A, Sauerwein WAG. Strategic Clinical Trial Design for Boron Neutron Capture Therapy. Cancer Biother Radiopharm 2023; 38:195-200. [PMID: 37023401 DOI: 10.1089/cbr.2022.0074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
Abstract
Boron neutron capture therapy (BNCT) involves infusion of cancer patients with a tumor-seeking, boron-loaded compound and irradiation by a beam of neutrons, with an energy range of 1 eV-10 keV. Neutron capture in the 10B atoms results in an effective lethal radiation dose to the tumor cells, while sparing the healthy tissue. Recently available accelerator-based irradiation facilities facilitate developing BNCT to a treatment modality. However, the binary principle of BNCT, together with other points, is challenging in designing clinical trials that allow a timely and safe introduction of this innovative targeted modality into clinical practice. We propose a methodological framework to work toward a systematic, coordinated, and internationally accepted and evidence-based approach.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiotherapy and Radiation Oncology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
| | - Wolfgang A G Sauerwein
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie (DGBNCT), Essen, Germany
- BNCT Global GmbH, Essen, Germany
| |
Collapse
|
3
|
C. STOCKERT JUAN, A. ROMERO SILVINA, N. FELIX-POZZI MARCELO, BL罿QUEZ-CASTRO ALFONSO. In vivo polymerization of the dopamine-borate melanin precursor: A proof-of-concept regarding boron neutron-capture therapy for melanoma. BIOCELL 2023. [DOI: 10.32604/biocell.2023.026631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
|
4
|
Dai Q, Yang Q, Bao X, Chen J, Han M, Wei Q. The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT). Mol Pharm 2022; 19:363-377. [PMID: 35040321 DOI: 10.1021/acs.molpharmaceut.1c00810] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Boron neutron capture therapy (BNCT) is a selective biological targeted nuclide technique for cancer therapy. It has the following attractive features: good targeting, high effectiveness, and causes slight damage to surrounding healthy tissue compared with other traditional methods. It has been considered as one of the promising methods for the treatment of various cancers. Measuring 10B concentrations is vital for BNCT. However, the existing technology and equipment cannot satisfy the real-time and accurate measurement requirements, and more efficient methods are in demand. The development of methods and imaging applied in BNCT to help measure boron concentration is described in this review.
Collapse
Affiliation(s)
- Qi Dai
- Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P.R. China.,Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, P.R. China
| | - QiYao Yang
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, P.R. China
| | - Xiaoyan Bao
- Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P.R. China
| | - Jiejian Chen
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, P.R. China
| | - Min Han
- Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P.R. China
| | - Qichun Wei
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, P.R. China
| |
Collapse
|
5
|
Dose-Dependent Suppression of Human Glioblastoma Xenograft Growth by Accelerator-Based Boron Neutron Capture Therapy with Simultaneous Use of Two Boron-Containing Compounds. BIOLOGY 2021; 10:biology10111124. [PMID: 34827117 PMCID: PMC8615214 DOI: 10.3390/biology10111124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 10/21/2021] [Accepted: 10/28/2021] [Indexed: 11/17/2022]
Abstract
Simple Summary Accelerator-based boron neutron capture therapy (BNCT) has opened up new perspectives in increasing cancer treatment efficacy, including malignant brain tumors and particularly glioblastoma. We studied dosimetry control optimization, neutron beam parameter adjustment, and two boron compound combinations (along with single and double irradiation regimens) to assess safety and increase therapy efficacy, using a U87MG xenotransplant immunodeficient mouse model. In two sets of experiments, we achieved increases in tumor-growth inhibition (to 80–83%), a neutron capture therapy ratio of 2:1 (two times higher neutron capture therapy efficacy than neutron irradiation without boron), and increases in animal life expectancy, from 9 to 107 days, by treatment parameter adjustment. These results will contribute to the development of clinical-trial protocols for accelerator-based BNCT and further innovations in this cancer treatment method. Abstract (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograft-bearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two 10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.
Collapse
|
6
|
Theranostics in Boron Neutron Capture Therapy. Life (Basel) 2021; 11:life11040330. [PMID: 33920126 PMCID: PMC8070338 DOI: 10.3390/life11040330] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.
Collapse
|
7
|
Fukuo Y, Hattori Y, Kawabata S, Kashiwagi H, Kanemitsu T, Takeuchi K, Futamura G, Hiramatsu R, Watanabe T, Hu N, Takata T, Tanaka H, Suzuki M, Miyatake SI, Kirihata M, Wanibuchi M. The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model. BIOLOGY 2020; 9:biology9120437. [PMID: 33271972 PMCID: PMC7759915 DOI: 10.3390/biology9120437] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 11/26/2020] [Accepted: 11/29/2020] [Indexed: 11/22/2022]
Abstract
Simple Summary We have developed a new boron compound for application in boron neutron capture therapy (BNCT) named boronophenylalanine–amide alkyl dodecaborate (BADB). It is characterized by a larger amount of 10B per molecule, linking boronphenylalanine (BPA) and dodecaborate, and we conducted various experiments on its efficacy. Its high accumulation at the cellular level made it a promising novel drug, but it did not sufficiently accumulate in brain tumor tissue when intravenously administered. However, in neutron irradiation experiments, the drug showed remarkably high compound biological effectiveness and significantly prolonged the survival time in rat brain tumor models. We confirmed the antitumor efficacy of BADB in BNCT and its additional efficacy when administered in combination with BPA. Though this drug showed poor results when administered as a single agent, it was superior to BPA alone when administered in combination with BPA, making it a drug that we have been waiting for in our clinical practice. Abstract Background: The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine–amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model. Methods: The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time. Results: The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group. Conclusion: BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.
Collapse
Affiliation(s)
- Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Yoshihide Hattori
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai-shi, Osaka 599-8531, Japan; (Y.H.); (M.K.)
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
- Correspondence: ; Tel.: +81-72-683-1221
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Takuya Kanemitsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Koji Takeuchi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Gen Futamura
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Mitsunori Kirihata
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai-shi, Osaka 599-8531, Japan; (Y.H.); (M.K.)
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| |
Collapse
|
8
|
Synthesis and Evaluation of Dodecaboranethiol Containing Kojic Acid (KA-BSH) as a Novel Agent for Boron Neutron Capture Therapy. Cells 2020; 9:cells9061551. [PMID: 32630612 PMCID: PMC7349888 DOI: 10.3390/cells9061551] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 06/18/2020] [Accepted: 06/23/2020] [Indexed: 11/17/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a form of tumor-cell selective particle irradiation using low-energy neutron irradiation of boron-10 (10B) to produce high-linear energy transfer (LET) alpha particles and recoiling 7Li nuclei (10B [n, alpha] 7Li) in tumor cells. Therefore, it is important to achieve the selective delivery of large amounts of 10B to tumor cells, with only small amounts of 10B to normal tissues. To develop practical materials utilizing 10B carriers, we designed and synthesized novel dodecaboranethiol (BSH)-containing kojic acid (KA-BSH). In the present study, we evaluated the effects of this novel 10B carrier on cytotoxicity, 10B concentrations in F98 rat glioma cells, and micro-distribution of KA-BSH in vitro. Furthermore, biodistribution studies were performed in a rat brain tumor model. The tumor boron concentrations showed the highest concentrations at 1 h after the termination of administration. Based on these results, neutron irradiation was evaluated at the Kyoto University Research Reactor Institute (KURRI) with KA-BSH. Median survival times (MSTs) of untreated and irradiated control rats were 29.5 and 30.5 days, respectively, while animals that received KA-BSH, followed by neutron irradiation, had an MST of 36.0 days (p = 0.0027, 0.0053). Based on these findings, further studies are warranted in using KA-BSH as a new B compound for malignant glioma.
Collapse
|
9
|
Hattori Y, Ishimura M, Ohta Y, Takenaka H, Kirihata M. Visualization of Boronic Acid Containing Pharmaceuticals in Live Tumor Cells Using a Fluorescent Boronic Acid Sensor. ACS Sens 2016. [DOI: 10.1021/acssensors.6b00522] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yoshihide Hattori
- Research
Center of Boron Neutron Capture Therapy, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan
| | - Miki Ishimura
- Research
Center of Boron Neutron Capture Therapy, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan
| | - Yoichiro Ohta
- Research
Center of Boron Neutron Capture Therapy, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan
| | - Hiroshi Takenaka
- Research
Center of Boron Neutron Capture Therapy, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan
| | - Mitsunori Kirihata
- Research
Center of Boron Neutron Capture Therapy, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan
| |
Collapse
|
10
|
Hattori Y, Ishimura M, Ohta Y, Takenaka H, Watanabe T, Tanaka H, Ono K, Kirihata M. Detection of boronic acid derivatives in cells using a fluorescent sensor. Org Biomol Chem 2015; 13:6927-30. [PMID: 26022725 DOI: 10.1039/c5ob00753d] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The detection of boron-containing compounds requires very expensive facilities and/or tedious sample pretreatments. In an effort to develop a convenient detection method for boronic acid derivatives, boron chelating-ligands were synthesized for use as fluorescent sensors. In this paper, the synthesis and properties of fluorescent sensors for boronic acid derivatives are reported.
Collapse
Affiliation(s)
- Yoshihide Hattori
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Wittig A, Moss RL, Sauerwein WA. Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT. Appl Radiat Isot 2014; 88:46-9. [DOI: 10.1016/j.apradiso.2013.11.038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Accepted: 11/18/2013] [Indexed: 11/25/2022]
|
12
|
Ye H, Gemperline E, Li L. A vision for better health: mass spectrometry imaging for clinical diagnostics. Clin Chim Acta 2012; 420:11-22. [PMID: 23078851 DOI: 10.1016/j.cca.2012.10.018] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Accepted: 10/09/2012] [Indexed: 12/13/2022]
Abstract
BACKGROUND Mass spectrometry imaging (MSI) is a powerful tool that grants the ability to investigate a broad mass range of molecules from small molecules to large proteins by creating detailed distribution maps of selected compounds. Its usefulness in biomarker discovery towards clinical applications has obtained success by correlating the molecular expression of tissues acquired from MSI with well-established histology. RESULTS To date, MSI has demonstrated its versatility in clinical applications, such as biomarker diagnostics of different diseases, prognostics of disease severities and metabolic response to drug treatment, etc. These studies have provided significant insight in clinical studies over the years and current technical advances are further facilitating the improvement of this field. Although the underlying concept is simple, factors such as choice of ionization method, sample preparation, instrumentation and data analysis must be taken into account for successful applications of MSI. Herein, we briefly reviewed these key elements yet focused on the clinical applications of MSI that cannot be addressed by other means. CONCLUSIONS Challenges and future perspectives in this field are also discussed to conclude that the ever-growing applications with continuous development of this powerful analytical tool will lead to a better understanding of the biology of diseases and improvements in clinical diagnostics.
Collapse
Affiliation(s)
- Hui Ye
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705-2222, USA
| | | | | |
Collapse
|
13
|
Hattori Y, Kusaka S, Mukumoto M, Uehara K, Asano T, Suzuki M, Masunaga SI, Ono K, Tanimori S, Kirihata M. Biological evaluation of dodecaborate-containing L-amino acids for boron neutron capture therapy. J Med Chem 2012; 55:6980-4. [PMID: 22788992 DOI: 10.1021/jm300749q] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To develop a boron carrier for practical purposes, new boron-containing amino acids with an undecahydro-closo-dodecaboranylthio ([(10)B(12)H(11)S](2-)-) unit in the side chain of the α-amino acid have already been designed and synthesized. In the present paper, cytotoxicity, the incorporation amounts into tumor cells, and the tumor cell killing effects of these compounds were elucidated to evaluate their usefulness as boron carriers. Furthermore, the microdistribution of the amino acids in tumor cells was established.
Collapse
Affiliation(s)
- Yoshihide Hattori
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku 599-8531, Sakai, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Tyler BJ, Dambach S, Galla S, Peterson RE, Arlinghaus HF. Investigation of the Utility of Laser-Secondary Neutral Mass Spectrometry for the Detection of Polyaromatic Hydrocarbons in Individual Atmospheric Aerosol Particles. Anal Chem 2011; 84:76-82. [DOI: 10.1021/ac2008338] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Bonnie J. Tyler
- Departments of Chemical Engineering and Chemistry, University of the West Indies, St. Augustine, Trinidad and Tobago
| | - Steffen Dambach
- Physikalisches Institut, University of Muenster, Wilhelm-Klemm-Strausse 10, 48149 Muenster, Germany
| | - Sebastian Galla
- Physikalisches Institut, University of Muenster, Wilhelm-Klemm-Strausse 10, 48149 Muenster, Germany
| | - Richard E. Peterson
- Departments of Chemical Engineering and Chemistry, University of the West Indies, St. Augustine, Trinidad and Tobago
| | - Heinrich F. Arlinghaus
- Physikalisches Institut, University of Muenster, Wilhelm-Klemm-Strausse 10, 48149 Muenster, Germany
| |
Collapse
|
15
|
Takahashi LK, Zhou J, Kostko O, Golan A, Leone SR, Ahmed M. Vacuum-Ultraviolet Photoionization and Mass Spectrometric Characterization of Lignin Monomers Coniferyl and Sinapyl Alcohols. J Phys Chem A 2011; 115:3279-90. [DOI: 10.1021/jp111437e] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Lynelle K. Takahashi
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
- Department of Chemistry, University of California at Berkeley, Berkeley, California 94720, United States
| | - Jia Zhou
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Oleg Kostko
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Amir Golan
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Stephen R. Leone
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
- Department of Chemistry, University of California at Berkeley, Berkeley, California 94720, United States
- Department of Physics, University of California at Berkeley, Berkeley, California 94720, United States
| | - Musahid Ahmed
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| |
Collapse
|
16
|
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot 2011; 69:1807-12. [PMID: 21367608 DOI: 10.1016/j.apradiso.2011.02.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Revised: 02/05/2011] [Accepted: 02/10/2011] [Indexed: 11/23/2022]
Abstract
The system L-amino acid transporter (LAT1) imports p-boronophenylalanine (BPA) mainly into proliferating cells. This study investigates in three tumor entities whether the proportion of tumor cells expressing LAT1 and/or Ki67 correlates with BPA uptake. Tumors were analyzed for (10)B concentration with prompt gamma-ray spectroscopy and for Ki67 and LAT1 expressions with immunohistochemical methods. The proportion of LAT1-expressing cells was much higher (5-90%) than that of Ki67-expressing cells (0-20%) and cells expressing both Ki67 and LAT1 (0-5%). Neither LAT1 nor Ki67 expression predicted BPA uptake.
Collapse
|
17
|
Brewer TM, Szakal C, Gillen G. Method for improved secondary ion yields in cluster secondary ion mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:593-598. [PMID: 20155758 DOI: 10.1002/rcm.4423] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A method to increase useful yields of organic molecules is investigated by cluster secondary ion mass spectrometry (SIMS). Glycerol drops were deposited onto various inkjet-printed arrays and the organic molecules in the film were rapidly incorporated into the drop. The resulting glycerol/analyte drops were then probed with fullerene primary ions under dynamic SIMS conditions. High primary ion beam currents were shown to aid in the mixing of the glycerol drop, thus replenishing the probed area and sustaining high secondary ion yields. Integrated secondary ion signals for tetrabutylammonium iodide and cocaine in the glycerol drops were enhanced by more than a factor of 100 compared with an analogous area on the surface, and a factor of 1000 over the lifetime of the glycerol drop. Once the analyte of interest is incorporated into the glycerol microdrop, the solution chemistry can be tailored for enhanced secondary ion yields, with examples shown for cyclotrimethylenetrinitramine (RDX) chloride adduct formation. In addition, depositing localized glycerol drops may enhance analyte secondary ion count rates to high enough levels to allow for site-specific chemical maps of molecules in complex matrices such as biological tissues.
Collapse
Affiliation(s)
- Tim M Brewer
- Surface and Microanalysis Science Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
| | | | | |
Collapse
|
18
|
Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WAG. Biodistribution of (10)B for Boron Neutron Capture Therapy (BNCT) in a mouse model after injection of sodium mercaptoundecahydro-closo-dodecaborate and l-para-boronophenylalanine. Radiat Res 2009; 172:493-9. [PMID: 19772470 DOI: 10.1667/rr1700.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
In boron neutron capture therapy, the absorbed dose from the (10)B(n,alpha)(7)Li reaction depends on the (10)B concentration and (10)B distribution in the irradiated volume. Thus compounds used in BNCT should have tumor-specific uptake and low accumulation in normal tissues. This study compares in a mouse model the (10)B uptake in different organs as delivered by l-para-boronophenylalanine (BPA, 700 mg/kg body weight, i.p.) and/or sodium mercaptoundecahydro-closo-dodecaborate (BSH, 200 mg/kg body weight, i.p). After BSH injection, the (10)B concentration was high in kidneys (20 +/- 12 microg/g) and liver (20 +/- 12 microg/g) but was low in brain (1.0 +/- 0.8 microg/g) and muscle (1.9 +/- 1.2 microg/g). After BPA injection, the (10)B concentration was high in kidneys (38 +/- 25 microg/g) and spleen (17 +/- 8 microg/g) but low in brain (5 +/- 3 microg/g). After combined BPA and BSH injection, the effect on the absolute (10)B concentration was additive in all organs. The ratio of the (10)B concentrations in tissues and blood differed significantly for the two compounds depending on the compound combination, which implies a different uptake profile for normal organs.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, University Hospital Essen, Essen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Fernández B, Costa JM, Pereiro R, Sanz-Medel A. Inorganic mass spectrometry as a tool for characterisation at the nanoscale. Anal Bioanal Chem 2009; 396:15-29. [DOI: 10.1007/s00216-009-2959-6] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2009] [Revised: 07/02/2009] [Accepted: 07/07/2009] [Indexed: 11/30/2022]
|
20
|
Boxer SG, Kraft ML, Weber PK. Advances in imaging secondary ion mass spectrometry for biological samples. Annu Rev Biophys 2009; 38:53-74. [PMID: 19086820 DOI: 10.1146/annurev.biophys.050708.133634] [Citation(s) in RCA: 206] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Imaging mass spectrometry combines the power of mass spectrometry to identify complex molecules based on mass with sample imaging. Recent advances in secondary ion mass spectrometry have improved sensitivity and spatial resolution, so that these methods have the potential to bridge between high-resolution structures obtained by X-ray crystallography and cyro-electron microscopy and ultrastructure visualized by conventional light microscopy. Following background information on the method and instrumentation, we address the key issue of sample preparation. Because mass spectrometry is performed in high vacuum, it is essential to preserve the lateral organization of the sample while removing bulk water, and this has been a major barrier for applications to biological systems. Recent applications of imaging mass spectrometry to cell biology, microbial communities, and biosynthetic pathways are summarized briefly, and studies of biological membrane organization are described in greater depth.
Collapse
Affiliation(s)
- Steven G Boxer
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA.
| | | | | |
Collapse
|
21
|
Wittig A, Collette L, Appelman K, Bührmann S, Jäckel MC, Jöckel KH, Schmid KW, Ortmann U, Moss R, Sauerwein WAG. EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. J Cell Mol Med 2009; 13:1653-1665. [PMID: 19602035 DOI: 10.1111/j.1582-4934.2009.00856.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Boron neutron capture therapy (BNCT) provides highly targeted delivery of radiation through the limited spatial distribution of its effects. This translational research/phase I clinical trial investigates whether BNCT might be developed as a treatment option for squamous cell carcinoma of head and neck (SCCHN) relying upon preferential uptake of the two compounds, sodium mercaptoundecahydro-closo-dodecaborate (BSH) or L-para-boronophenylalanine (BPA) in the tumour. Before planned tumour resection, three patients received BSH and three patients received BPA. The (10)B-concentration in tissues and blood was measured with prompt gamma ray spectroscopy. Adverse effects from compounds did not occur. After BPA infusion the (10)B-concentration ratio of tumour/blood was 4.0 +/- 1.7. (10)B-concentration ratios of tumour/normal tissue were 1.3 +/- 0.5 for skin, 2.1 +/- 1.2 for muscle and 1.4 +/- 0.01 for mucosa. After BSH infusion the (10)B-concentration ratio of tumour/blood was 1.2 +/- 0.4. (10)B-concentration ratios of tumour/normal tissue were 3.6 +/- 0.6 for muscle, 2.5 +/- 1.0 for lymph nodes, 1.4 +/- 0.5 for skin and 1.0 +/- 0.3 for mucosa. BPA and BSH deliver (10)B to SCCHN to an extent that might allow effective BNCT treatment. Mucosa and skin are the most relevant organs at risk.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Laurence Collette
- Statistics Department, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - Klaas Appelman
- Nuclear Research and consultancy Group (NRG), Petten, The Netherlands
| | - Sandra Bührmann
- Pharmacy of the University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Martin C Jäckel
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Karl-Heinz Jöckel
- Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Kurt Werner Schmid
- Institute of Pathology and Neuropathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Uta Ortmann
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Raymond Moss
- HFR Unit, Institute for Energy, Joint Research Centre, European Commission, Petten, The Netherlands
| | - Wolfgang A G Sauerwein
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
22
|
Wittig A, Collette L, Moss R, Sauerwein W. Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001. Appl Radiat Isot 2009; 67:S59-62. [DOI: 10.1016/j.apradiso.2009.03.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Current Opinion in Oncology. Current world literature. Curr Opin Oncol 2009; 21:386-92. [PMID: 19509503 DOI: 10.1097/cco.0b013e32832e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Takahashi LK, Zhou J, Wilson KR, Leone SR, Ahmed M. Imaging with Mass Spectrometry: A Secondary Ion and VUV-Photoionization Study of Ion-Sputtered Atoms and Clusters from GaAs and Au. J Phys Chem A 2009; 113:4035-44. [DOI: 10.1021/jp810408v] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Lynelle K. Takahashi
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Chemistry, and Department of Physics, University of California at Berkeley, Berkeley, California 94720
| | - Jia Zhou
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Chemistry, and Department of Physics, University of California at Berkeley, Berkeley, California 94720
| | - Kevin R. Wilson
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Chemistry, and Department of Physics, University of California at Berkeley, Berkeley, California 94720
| | - Stephen R. Leone
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Chemistry, and Department of Physics, University of California at Berkeley, Berkeley, California 94720
| | - Musahid Ahmed
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Chemistry, and Department of Physics, University of California at Berkeley, Berkeley, California 94720
| |
Collapse
|